Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

PIN Pharma to Present a Poster at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

PIN Pharma,Inc.
Posted on: 19 Sep 16

PIN Pharma, a pre-clinical immunotherapy company focused on modulating the immune system in oncology, today announced the Company will be presenting PIN-2: A Novel Immunopriming Peptide with Immunomodulatory Activity Linking the Innate and Adaptive Immune Systems at Poster Session B on Monday, September 26, 2016 from 5:30 pm – 8:00 pm.

About PIN Pharma, Inc.

PIN Pharma is a pre-clinical stage venture backed immunotherapy company focused on the development of PINS (precision immune stimulants). The lead compound PIN-2 is a first-in-class, novel, next-generation engineered peptide that empowers the immune system in vivo. The Company’s technology primes the innate immune system to modulate adaptive immunity thereby generating and expanding antigen-specific cytotoxic T-cells in vivo. The company is advancing PIN-2 to the clinic early first quarter 2017.

For more information about PIN Pharma and PIN-2, contact Mark Smith, CBO ( or Colin Bier, CEO ( at PIN Pharma, Inc., 3960 Broadway, Suite 620, New York, NY, or call 212-543-2583.

View source version on

Business Wire

Last updated on: 19/09/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.